Francisco Epelde: Development and Validation of a Nomogram for Predicting Bleeding Risk in Patients with PE
Francisco Epelde, Attending Physician, internal Medicine Service at Parc Taulí University Hospital, posted on LinkedIn:
” ‘Development and Validation of a Nomogram for Predicting Bleeding Risk in Patients with Pulmonary Embolism’
DOI: 10.3389/fmed.2025.1692156
Authors: Tian Ye, Wanlin Lei, Maofeng Wang, Lili Xu
Read full article here or print here.
As Academic Editor, I had the privilege of overseeing this excellent study by Ye et al. (Wenzhou Medical University, China), which provides an important step toward personalized medicine in pulmonary embolism (PE) management.
Why this work matters:
Bleeding remains one of the most serious complications of anticoagulation therapy in PE. Current clinical scores—such as HAS-BLED or ATRIA—were not specifically developed for this population and often fail to capture the true hemorrhagic risk in acute PE settings.
This study overcomes that gap by developing and validating the first PE-specific bleeding risk nomogram, integrating six easily measurable clinical parameters: prior bleeding history, renal insufficiency, red blood cell count, systolic pressure, cerebral infarction, and creatinine.
Using data from 5,632 hospitalized patients, the model showed strong predictive performance (AUC 0.73–0.76) and was internally validated with excellent calibration. Importantly, decision curve analysis demonstrated clear clinical benefit—reducing major bleeding by up to 42% compared to standard care.
In essence, this paper exemplifies how data-driven tools can translate complex statistical modeling into bedside decision-making, supporting safer, more individualized anticoagulation strategies for patients with pulmonary embolism.”
Get insights from Hemostasis Today.
-
Aug 13, 2026, 11:15Bridging Neurology and Thrombosis: Key Priorities from a New Expert Consensus Report – International Journal of Stroke
-
Aug 13, 2026, 11:05Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
-
Aug 13, 2026, 10:31Brad Wilson: Clinical Insights from the Landmark ESC 2026 Trials
-
Aug 13, 2026, 10:23Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:44Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure